epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Alli
    orlistat
  • remove fingolimod
    generic
  • remove Glatopa
    glatiramer
  • remove Hydra-Zide
    hydralazine/ hydrochlorothiazide
  • remove Oxtellar XR
    oxcarbazepine
  • remove Trandate
    labetalol

multicheck MultiCheck Results - 5 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face fingolimod (generic) + Trandate (labetalol)

Avoid/Use Alternative


fingolimod + labetalol

use alternative or monitor BP, HR, ECG overnight, esp. during fingolimod initiation/titration: combo may incr. risk of PR interval prolongation, AV block, bradycardia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

Monitor/Modify Tx

Smiley face Smiley face fingolimod (generic) + Hydra-Zide (hydralazine/ hydrochlorothiazide)

Monitor/Modify Tx


fingolimod + hydralazine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

fingolimod + hydrochlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

Smiley face Smiley face Hydra-Zide (hydralazine/ hydrochlorothiazide) + Oxtellar XR (oxcarbazepine)

Monitor/Modify Tx


hydrochlorothiazide + oxcarbazepine

monitor sodium: combo may incr. risk of hyponatremia, seizures (additive effects)

Smiley face Smiley face Hydra-Zide (hydralazine/ hydrochlorothiazide) + Trandate (labetalol)

Monitor/Modify Tx


hydralazine + labetalol

monitor BP: combo may incr. risk of severe hypotension (additive effects)

Additional Considerations

Smiley face Smiley face orlistat in Alli

caution advised with concurrent oral narrow therapeutic index drugs with concerns for loss of efficacy; orlistat may decr. absorption of some oral drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information